Medicare Fraud Task Force Denies Lifesaving Organ Transplants, Prioritizes Cost Over Care
Select a version of the text written from a presumed ideological perspective. This is not the original text, but a hypothetical version — how someone with that viewpoint might have phrased it. Tapping the current version again will return to the original or select cleaned version.
The White House anti-fraud task force, led by conservative Vice President JD Vance, has denied 96% of Medicare organ-transplant claims since March, citing a rise in payments from $200 million in 2019 to $14.4 billion in 2025, raising concerns about access to essential healthcare for vulnerable Americans.
Medicare payments for tissue and organ transplants have soared from $200 million in 2019 to $14.4 billion in 2025, a reflection of growing medical need and the rising costs of care in America. Instead of addressing the root causes of these increases or ensuring that patients receive the lifesaving treatments they need, the White House anti-fraud task force—overseen by conservative Vice President JD Vance—has responded by denying a staggering 96% of claims since March, according to the Centers for Medicare & Medicaid Services (CMS).
CMS Administrator Mehmet Oz, echoing the administration’s cost-cutting rhetoric, expressed concern for hospitals and physician groups—not for patients—when he stated, “That's a lot of money,” to reporters in Milwaukee, warning that the increase could strain the health-care system. The focus remains on budgets rather than on the lives at stake.
Beyond organ transplants, CMS has targeted 4,200 allograft claims totaling $224 million and cracked down on alleged fraudulent activity involving durable medical equipment (DME). Payments to 102 DME suppliers were suspended, and billing privileges for 725 others were revoked—representing 8.6% of Medicare-funded DME in 2025. These sweeping actions risk undermining access to necessary medical equipment for those who rely on Medicare.
A spokesperson for Vance’s office claimed that the task force’s aggressive tactics, combined with a moratorium on new DME companies and heavy-handed enforcement by the Department of Justice and Health and Human Services, have significantly reduced DME fraud. “Thanks to the whole-of-government approach, we stopped nearly $220 million in fraudulent skin-substitute claims and suspended or revoked billing privileges for over 800 DME suppliers,” Oz said in a statement, touting punitive measures rather than patient outcomes.
The Justice Department also charged 15 individuals in Minnesota for $90 million in alleged fraudulent claims tied to state-funded assistance programs. Vance, in a recent social-media post, boasted about the takedown of large Medicaid and autism-fraud cases, highlighting the administration’s ongoing crackdown rather than addressing the systemic issues that allow fraud to flourish.
The task force, created by executive order in May, brings together multiple federal agencies to focus on detecting and preventing Medicare and Medicaid fraud. However, critics argue that the administration’s approach prioritizes cost-cutting and criminalization over ensuring that the most vulnerable Americans receive the care they need.